Rheumatology International

, Volume 31, Issue 11, pp 1487–1492

Incidence of malignancy in Japanese patients with rheumatoid arthritis

  • Toru Yamada
  • Ayako Nakajima
  • Eisuke Inoue
  • Eiichi Tanaka
  • Atsuo Taniguchi
  • Shigeki Momohara
  • Hisashi Yamanaka
Original Article


To determine the incidence of malignancy and site-specific malignancies in Japanese patients with rheumatoid arthritis (RA). In a prospective large observational cohort study named IORRA, 7,566 patients with RA were enrolled from April 2001 to April 2005 and were followed up to October 2005. Occurrence of malignancy was originally collected by patient reports of IORRA survey biannually from April 2001 to October 2005, and was confirmed by medical records. Standardized incidence rate (SIR) of the observed-to-expected cancer incidence and 95% confidence intervals (95% CI) were then calculated. Factors obtained at first enrollment in IORRA were assessed for association with risk of malignancy using the Cox proportional hazards model. A total of 177 malignancies in 173 patients (58 in men, 115 in women) were identified during the observation period of 25,567 person-years. The age- and sex-standardized incidence rate of malignancy was 437.1 (men, 706.8; women, 366.1) per 100,000 person-years. The SIR of malignancy was slightly excess (SIR 1.18, [95% CI 1.02–1.37]) in all patients, but 1.29 (95% CI 0.99–1.67) in men, and 1.13 (95% CI 0.94–1.36) in women. A significant excess of lymphoma (SIR 6.07, [95% CI 3.71–9.37]) and lung cancer (SIR 2.29, [95% CI 1.57–3.21]), whereas decreased incidence of colorectal cancer (SIR 0.49, [95% CI 0.26–0.83]), were found. Male gender and older age were identified as risk factors for malignancy. A slight excess in the incidence of overall malignancy and highly excess of lymphoma in Japanese RA patients was demonstrated.


Rheumatoid arthritis Malignancy Cancer Incidence Risk factor Comorbidity Lymphoma Lung cancer 


  1. 1.
    Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2002) Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29:62–67PubMedGoogle Scholar
  2. 2.
    Young A, Koduri G, Batley M et al (2007) Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46:350–357CrossRefGoogle Scholar
  3. 3.
    Kuroda T, Tanabe N, Harada T et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505PubMedCrossRefGoogle Scholar
  4. 4.
    Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732PubMedCrossRefGoogle Scholar
  5. 5.
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 24:445–451PubMedGoogle Scholar
  6. 6.
    Hoshida Y, Xu JX, Fujita S et al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331PubMedGoogle Scholar
  7. 7.
    Smitten AL, Choi HK, Hochberg MC et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393PubMedGoogle Scholar
  8. 8.
    Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45PubMedCrossRefGoogle Scholar
  9. 9.
    Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 37:388–397PubMedCrossRefGoogle Scholar
  10. 10.
    Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37:31–38PubMedCrossRefGoogle Scholar
  11. 11.
    Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2007) Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56:790–798PubMedCrossRefGoogle Scholar
  12. 12.
    Geborek P, Bladstrom A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedCrossRefGoogle Scholar
  13. 13.
    Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R (1984) Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43:128–131PubMedCrossRefGoogle Scholar
  14. 14.
    Cibere J, Sibley J, Haga M (1997) Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580–1586PubMedCrossRefGoogle Scholar
  15. 15.
    Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158PubMedCrossRefGoogle Scholar
  16. 16.
    Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414–1420PubMedCrossRefGoogle Scholar
  17. 17.
    Setoguchi S, Solomon DH, Weinblatt ME et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764PubMedCrossRefGoogle Scholar
  18. 18.
    Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757PubMedCrossRefGoogle Scholar
  19. 19.
    Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502PubMedCrossRefGoogle Scholar
  20. 20.
    Georgescu L, Quinn GC, Schwartzman S, Paget SA (1997) Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26:794–804PubMedCrossRefGoogle Scholar
  21. 21.
    Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701PubMedCrossRefGoogle Scholar
  22. 22.
    Kojima M, Itoh H, Hirabayashi K et al (2006) Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract 202:679–685PubMedCrossRefGoogle Scholar
  23. 23.
    Shinomiya F, Mima N, Nanba K et al (2008) Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheumatol 18:165–169PubMedCrossRefGoogle Scholar
  24. 24.
    Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, Shidara K, Hara M, Momohara S, Taniguchi A, Kamatani N, Yamanaka H (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol (in press)Google Scholar
  25. 25.
    Yamanaka H, Inoue E, Singh G et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289PubMedCrossRefGoogle Scholar
  26. 26.
    Yamada T, Nakajima A, Inoue E et al (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661–1663PubMedCrossRefGoogle Scholar
  27. 27.
    Nakajima A, Kamitsuji S, Saito A et al (2006) Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol 16:151–157PubMedCrossRefGoogle Scholar
  28. 28.
    Matsuda Y, Singh G, Yamanaka H et al (2003) Validation of a Japanese version of the Stanford health assessment questionnaire in 3, 763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788PubMedCrossRefGoogle Scholar
  29. 29.
    Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2008) Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38:641–648PubMedCrossRefGoogle Scholar
  30. 30.
    Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS (1992) Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19:1462–1465PubMedGoogle Scholar
  31. 31.
    Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996) Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 39:325–329PubMedCrossRefGoogle Scholar
  32. 32.
    Hoshida Y, Tomita Y, Zhiming D et al (2004) Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 108:443–449PubMedCrossRefGoogle Scholar
  33. 33.
    Rizzi R, Curci P, Delia M et al (2009) Spontaneous remission of “Methotrexate-associated lymphoproliferative disorders” After discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26:1–9PubMedCrossRefGoogle Scholar
  34. 34.
    Miyazaki T, Fujimaki K, Shirasugi Y et al (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82:1106–1109PubMedCrossRefGoogle Scholar
  35. 35.
    Bernatsky S, Clarke A, Suissa S (2008) Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung Cancer 59:266–269PubMedCrossRefGoogle Scholar
  36. 36.
    Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Toru Yamada
    • 1
  • Ayako Nakajima
    • 1
  • Eisuke Inoue
    • 1
  • Eiichi Tanaka
    • 1
  • Atsuo Taniguchi
    • 1
  • Shigeki Momohara
    • 1
  • Hisashi Yamanaka
    • 1
  1. 1.Institute of RheumatologyTokyo Women’s Medical UniversityShinjuku-ku, TokyoJapan

Personalised recommendations